Bank of America Cuts Church & Dwight (NYSE:CHD) Price Target to $105.00

Church & Dwight (NYSE:CHD) had its price target trimmed by Bank of America from $120.00 to $105.00 in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also weighed in on CHD. Barclays lowered their target price on Church & Dwight from $84.00 to $83.00 and set an “underweight” rating for the company in a report on Monday, August 4th. Redburn Atlantic lowered Church & Dwight from a “hold” rating to a “strong sell” rating in a report on Monday, July 14th. UBS Group decreased their price objective on Church & Dwight from $103.00 to $98.00 and set a “neutral” rating for the company in a report on Wednesday. Redburn Partners set a $83.00 price objective on Church & Dwight in a report on Monday, July 14th. Finally, Wall Street Zen upgraded Church & Dwight from a “sell” rating to a “hold” rating in a report on Saturday, June 21st. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, Church & Dwight presently has a consensus rating of “Hold” and a consensus price target of $100.88.

Church & Dwight Stock Down 0.0%

Church & Dwight stock opened at $87.61 on Wednesday. The business has a fifty day moving average of $91.38 and a two-hundred day moving average of $96.19. The company has a quick ratio of 1.33, a current ratio of 1.84 and a debt-to-equity ratio of 0.50. The firm has a market cap of $21.34 billion, a P/E ratio of 41.33, a P/E/G ratio of 3.64 and a beta of 0.43. Church & Dwight has a twelve month low of $85.08 and a twelve month high of $116.46.

Church & Dwight (NYSE:CHD) last posted its earnings results on Friday, August 1st. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.48 billion. Church & Dwight had a return on equity of 19.27% and a net margin of 8.66%.Church & Dwight’s revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.93 earnings per share. Church & Dwight has set its FY 2025 guidance at 3.440-3.510 EPS. Q3 2025 guidance at 0.720-0.720 EPS. On average, analysts forecast that Church & Dwight will post 3.7 earnings per share for the current fiscal year.

Church & Dwight Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, August 15th were paid a $0.295 dividend. The ex-dividend date was Friday, August 15th. This represents a $1.18 dividend on an annualized basis and a yield of 1.3%. Church & Dwight’s dividend payout ratio (DPR) is 55.66%.

Insider Buying and Selling

In other news, EVP Lee B. Mcchesney bought 5,409 shares of Church & Dwight stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $91.38 per share, for a total transaction of $494,274.42. Following the purchase, the executive vice president directly owned 5,409 shares of the company’s stock, valued at approximately $494,274.42. The trade was a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Read bought 2,000 shares of Church & Dwight stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average price of $91.27 per share, with a total value of $182,540.00. Following the purchase, the executive vice president directly owned 7,505 shares in the company, valued at $684,981.35. The trade was a 36.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 12,879 shares of company stock worth $1,177,702 in the last 90 days. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Church & Dwight

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Church & Dwight by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 31,830,529 shares of the company’s stock worth $3,059,232,000 after purchasing an additional 388,890 shares during the period. State Street Corp grew its position in Church & Dwight by 3.0% during the 2nd quarter. State Street Corp now owns 13,467,055 shares of the company’s stock worth $1,294,319,000 after purchasing an additional 387,667 shares during the period. Geode Capital Management LLC grew its position in Church & Dwight by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 6,290,207 shares of the company’s stock worth $601,991,000 after purchasing an additional 177,990 shares during the period. Invesco Ltd. grew its position in Church & Dwight by 25.1% during the 2nd quarter. Invesco Ltd. now owns 3,510,113 shares of the company’s stock worth $337,357,000 after purchasing an additional 703,171 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Church & Dwight by 0.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,269,079 shares of the company’s stock worth $319,193,000 after purchasing an additional 29,369 shares during the period. 86.60% of the stock is owned by institutional investors and hedge funds.

About Church & Dwight

Church & Dwight Co, Inc engages in the development, manufacture, and marketing of household, personal care, and specialty products. It operates through the following segments: Consumer Domestic, Consumer International, Specialty Products Division (SPD), and Corporate. The Consumer Domestic segment offers household products, such as laundry detergents, fabric softener sheets, cat litter, household cleaning products, and personal care products including antiperspirants, oral care products, depilatories, reproductive health products, oral analgesics, nasal saline moisturizers, and dietary supplements.